Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

 Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated with COVID-19

Shots:

  • The first patient has been dosed in a P-II study of TD-0903. The P-II study consists of two parts: the first part will assess the safety, tolerability, and clinical response to treatment in sequential ascending dose cohorts of hospitalized COVID-19 patients, with each patient demonstrating hypoxia being dosed for 7 days
  • The second part will be conducted at hospital-based clinical sites in the UK, EU & the US, pending appropriate Ethics Committee, and regulatory approvals in territories. The P-II study in the UK follows the completion of dosing in the P-I study in healthy volunteers
  • TD-0903 is a lung-selective, nebulized pan-JAK inhibitor, being developed to treat hospitalized patients with ALI caused by COVID-19

Click here to read full press release/ article | Ref: Theravance | Image: Theravance

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post